ContraVir Pharmaceuticals, Inc.
399 Thornall Street
Edison, NJ 08837
| June 14, 2019 |
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Dorrie Yale
Re: ContraVir Pharmaceuticals, Inc.
Form S-1, as amended
File No. 333-231604
Dear Ms. Yale:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Standard Time, on Monday, June 17, 2019, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
| Thank you, | |
|
| |
| CONTRAVIR PHARMACEUTICALS, INC. | |
|
| |
|
| |
| By: | /s/ Robert Foster |
| Name: | Robert Foster |
| Title: | Chief Executive Officer |
